Concepedia

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Brian I. Rini, Thomas Powles, Michael B. Atkins, Bernard Escudier, David F. McDermott, Cristina Suárez, Sergio Bracarda, Walter M. Stadler, Frede Donskov, Jae‐Lyun Lee,

The Lancet · 2019 · 1K citations · 22 references

DOI

Concepts

References

22

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text

, , +17

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Nizar M. Tannir, Osvaldo Arén Frontera et al. · New England Journal of Medicine · 2018 · 4.6K citations · Full text

, , +11

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Bernard Escudier, Camillo Porta, Manuela Schmidinger et al. · Annals of Oncology · 2014 · 2.3K citations · Full text

, , +14

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

Dmitry I. Gabrilovich, Hailei L. Chen, Khaled R. Girgis et al. · Nature Medicine · 1996 · 2K citations

, , +13

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, David Cella et al. · New England Journal of Medicine · 2013 · 1.9K citations · Full text

, , +13